Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25 USD | +0.89% | -1.78% | -13.79% |
May. 10 | Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating | MT |
May. 08 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.79% | 1.17B | |
+29.65% | 48.16B | |
-1.01% | 41.73B | |
+43.34% | 41.03B | |
-5.31% | 28.77B | |
+10.22% | 25.59B | |
-21.21% | 18.96B | |
+6.70% | 12.92B | |
+26.92% | 12.03B | |
-3.10% | 11.77B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Transcript : Mirum Pharmaceuticals, Inc. Presents at UBS Biopharma Conference 2023, Nov-08-2023 02